Fulcrum Therapeutics
FULC
67 hedge funds and large institutions have $281M invested in Fulcrum Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 11 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.38% less ownership
Funds ownership: 82.38% → 82% (-0.38%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 68 → 67 (-1)
11% less capital invested
Capital invested by funds: $317M → $281M (-$36.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$4.43M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.15M |
| 3 |
PA
Perceptive Advisors
New York
|
+$2.97M |
| 4 |
ACM
Altium Capital Management
New York
|
+$2.16M |
| 5 |
BlackRock
New York
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.3M |
| 2 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$3.77M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.67M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.49M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$135K | -11,460 | Closed |
|
77
Acadian Asset Management
Boston,
Massachusetts
| – | -$41K | -3,471 | Closed |
|
|
PHK
78
Point72 Hong Kong
Hong Kong
| – | -$1K | -90 | Closed |
|
FULC Hedge Fund Activity: Q2 2021 in Review
67 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q2 2021, worth a combined $281M — down 11% from $317M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of FULC and 10 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 30 added.
The largest buyer was Cowen and Company, adding an estimated $4.43M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $10.3M sold.
- 67 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2021, down from 68 in Q1 2021.
- Funds reported $281M of Fulcrum Therapeutics stock for Q2 2021, down 11% quarter-over-quarter.
- 10 funds opened new Fulcrum Therapeutics positions in Q2 2021 and 11 closed out, a net change of -1 holder.
- The largest Fulcrum Therapeutics buyer in Q2 2021 was Cowen and Company, an estimated $4.43M added.
- The largest Fulcrum Therapeutics seller in Q2 2021 was Driehaus Capital Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2021.